Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Diquafosol tetrasodium, 2% · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 2 | PLACEBO_COMPARATOR | - |
| Arm 1 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Diquafosol tetrasodium ophthalmic solution, 2% | DRUG | One to two drops in each eye QID for 6 weeks |
| Placebo | DRUG | One to two drops in each eye QID for 6 weeks |
| Non-preserved saline solution (Placebo) | DRUG | 1-2 drops administered in each eye 4 times a day for 6 weeks |
Inclusion Criteria: * Have best corrected visual acuity in both eyes of at least +0.7 or better * Central corneal staining of 3 on the NEI scale * If female, are non-pregnant or non-lactating * Have a history of dry eye disease in both eyes * Have normal lid anatomy Exclusion Criteria: * Unable t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
Diquafosol tetrasodium, 2% is an investigational small molecule being developed for the treatment of Dry Eye Disease. It is an ophthalmic solution administered as eye drops. The drug is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Diquafosol tetrasodium, 2% is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is in Phase 3 clinical trials for Dry Eye Disease.
Diquafosol tetrasodium, 2% is in Phase 3 clinical development for Dry Eye Disease. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. Three Phase 3 trials have been completed, with a total enrollment of 1,391 participants.
Diquafosol tetrasodium, 2% has completed three Phase 3 clinical trials: NCT00403975 with 640 participants, NCT00600288 with 261 participants, and NCT00831662 with 490 participants. All trials were randomized, double-blind, placebo-controlled studies in patients with Dry Eye Disease.
Diquafosol tetrasodium, 2% is a small molecule that acts as a P2Y2 receptor agonist. It stimulates tear secretion and mucin production on the ocular surface, which helps to alleviate the symptoms of Dry Eye Disease. The drug is administered as an ophthalmic solution.